Sugi Predict

Sugi Predict / Compounds / SCHEMBL317351

SCHEMBL317351

SCHEMBL317351

[NH]Cc1ccc(-c2ccc(F)cc2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 5/20 0.54
▸ CYP11B2 P19099 5/20 0.54
▸ MET P08581 3/20 0.54
▸ AURKA O14965 1/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ NTRK1 P04629 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ CSF1R P07333 1/20 0.54
▸ RET P07949 1/20 0.54
▸ PDGFRB P09619 1/20 0.54
▸ PIM1 P11309 1/20 0.54
▸ PDGFRA P16234 1/20 0.54
▸ FLT3 P36888 1/20 0.54
▸ MAPK8 P45983 1/20 0.54
▸ CDK8 P49336 1/20 0.54
▸ MAP2K1 Q02750 1/20 0.54
▸ MAP4K2 Q12851 1/20 0.54
▸ ROCK1 Q13464 1/20 0.54
▸ NTRK3 Q16288 1/20 0.54
▸ MAPK14 Q16539 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL317352 0.81 CYP11B1 (0.54) CYP11B1CYP11B2METAURKAABL1
SCHEMBL9602018 0.81 NPC1 (0.61) CYP11B1CYP11B2METAURKAABL1
SCHEMBL21035639 0.81 CYP11B1 (0.54) CYP11B1CYP11B2METAURKAABL1
SCHEMBL2216313 0.81 FYN (0.56) CYP11B1CYP11B2METAURKAABL1
SCHEMBL14268230 0.80 CYP11B1 (0.52) CYP11B1CYP11B2METAURKAABL1
SCHEMBL27705919 0.79 CYP11B1 (0.51) CYP11B1CYP11B2METAURKAABL1
SCHEMBL8452469 0.77 SMN1; SMN2 (0.62) CYP11B1CYP11B2METAURKAABL1
SCHEMBL4415823 0.77 MET (0.65) CYP11B1CYP11B2METAURKAABL1
SCHEMBL4590904 0.76 RAB9A (0.52) CYP11B1CYP11B2METAURKAABL1
SCHEMBL3822972 0.75 NPC1 (0.46) CYP11B1CYP11B2METAURKAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585069-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN Janssen Pharmaceutica, N.V. (BE) 2013-05-01 — — EP claimed
EP-1973886-B1 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2013-02-27 — — EP claimed
WO-2012006004-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN JANSSEN PHARMACEUTICA NV (BE) 2012-01-12 — — WO claimed
US-20110319400-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN JANSSEN PHARMACEUTICA, NV (BE) 2011-12-29 — — US claimed
EP-2385042-A1 Prokineticin 1 receptor antagonists Janssen Pharmaceutica N.V. (BE) 2011-11-09 — — EP claimed
US-8039028-B2 Use of an extract of the orchid Vanda coerulea as a skin hydrating agent LVMH REACHERCHE (FR) 2011-10-18 — — US claimed
US-7902358-B2 Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea JANSSEN PHARMACEUTICA NV (BE) 2011-03-08 — — US claimed
US-20080287445-A1 Prokineticin 2 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-11-20 — — US claimed
US-20080269225-A1 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-30 — — US claimed
EP-2385042-B1 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2015-11-25 — — EP disclosed
EP-2585069-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN Janssen Pharmaceutica, N.V. (BE) 2013-05-01 — — EP disclosed
EP-1973886-B1 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2013-02-27 — — EP disclosed
US-8372973-B2 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-12 — — US disclosed
US-20120028997-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS COATS STEVEN J (US) 2012-02-02 — — US disclosed
US-20080287445-A1 Prokineticin 2 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-11-20 — — US disclosed
US-20080269225-A1 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-30 — — US disclosed
EP-1976528-A2 PROKINETICIN 2 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2008-10-08 — — EP disclosed
EP-1973886-A2 PROKINETICIN 1 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2008-10-01 — — EP disclosed
WO-2007079214-A2 PROKINETICIN 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-12 — — WO disclosed
WO-2007079163-A2 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028997-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS PROKR1, PROKR2, GIPR CYP11B1 1236/4885CYP11B2 1448/4885MET 811/4885
US-20110319400-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN PROKR1, OPRL1, PROKR2 CYP11B1 4478/4885CYP11B2 4583/4885MET 3485/4885
US-20080269225-A1 Prokineticin 1 receptor antagonists PROKR1, PROKR2, GIPR CYP11B1 1236/4885CYP11B2 1448/4885MET 811/4885
US-20080287445-A1 Prokineticin 2 receptor antagonists PROKR2, PROKR1, GIPR CYP11B1 2230/4885CYP11B2 918/4885MET 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.